Overview of Ongoing Clinical Trials on Radioembolization

The role and data driven basis for radioembolization remains ill-deﬁned with recent phase III randomized trials negative for patients with hepatocellular carcinoma (HCC), and only a single second line trial in metastatic colorectal cancer (CRC) meeting its primary endpoint progression-free survival (EPOCH, NCT01483027) [1]. Few studies are currently underway to deﬁne and/or clarify the role of radioembolization. The search term ‘‘radioembolization OR SIRT OR TheraSphere OR TARE’’ (status: Aug. 2022), revealed 44 clinical trials at clinicaltrials.gov, of which only 25 are currently recruiting. However, additional active trials can be found in registries such as the European Union (cid:2) s register EudraCT (2 additional active trials) [2] or national such as the German DRKS (3 additional active trials) [3]. Stratifying ongoing clinical trials as published in PubMed or clinicaltrials.gov, the following categories can be deﬁned: (a) clinical trials evaluating the efﬁcacy of SIRT in different tumor biologies metastatic to or primaries of the liver; as the most important subgroup, evaluation of combination therapies with systemic treatment, predomi-nantly combining with checkpoint inhibition, including basic research seeking immune-modulating mechanisms and proof in tissue or blood; (b) assessing new technologies such as Holmium-166 for SIRT; and (c) new approaches (e.g., highly selected patient group) and indications for SIRT, also outside the liver. The only phase III trial ongoing likely is STOP-HCC (NCT01556490), with advanced HCC patients receiving sorafenib ± radioembolization. Primary endpoint is results are

The role and data driven basis for radioembolization remains ill-defined with recent phase III randomized trials negative for patients with hepatocellular carcinoma (HCC), and only a single second line trial in metastatic colorectal cancer (CRC) meeting its primary endpoint progressionfree survival (EPOCH, NCT01483027) [1]. Few studies are currently underway to define and/or clarify the role of radioembolization. The search term ''radioembolization OR SIRT OR TheraSphere OR TARE'' (status: Aug. 2022), revealed 44 clinical trials at clinicaltrials.gov, of which only 25 are currently recruiting. However, additional active trials can be found in registries such as the European Unions register EudraCT (2 additional active trials) [2] or national such as the German DRKS (3 additional active trials) [3]. Stratifying ongoing clinical trials as published in PubMed or clinicaltrials.gov, the following categories can be defined: (a) clinical trials evaluating the efficacy of SIRT in different tumor biologies metastatic to or primaries of the liver; as the most important subgroup, evaluation of combination therapies with systemic treatment, predominantly combining with checkpoint inhibition, including basic research seeking immune-modulating mechanisms and proof in tissue or blood; (b) assessing new technologies such as Holmium-166 for SIRT; and (c) new approaches (e.g., highly selected patient group) and indications for SIRT, also outside the liver.
The only phase III trial ongoing likely is STOP-HCC (NCT01556490), with advanced HCC patients receiving sorafenib ± radioembolization. Primary endpoint is overall survival, results are expected for end of 2022. However, this concept may come late given most recent developments in systemic HCC treatment shifting to immune checkpoint inhibition [4,5]. Considering the presumptive immunomodulatory effect of radioembolization such combination therapies might be the future domain of radioembolization, which is supported by the results of a recently published phase II study from Singapore (NCT03033446, radioembolization ? Nivolumab) [6] as well as by the promising preliminary results of a phase I (NCT03099564, radioembolization ? Pembrolizumab) [7] and phase II study (NCT03380130, radioembolization ? Nivolumab) [8]. Therefore, phase II trials such as IMMUWIN (NCT04522544; randomized, radioembolization or transarterial chemoembolization [ or neuroendocrine tumors (NCT03457948). Finally, the only active clinical cancer trial for non-liver indications seems to be POEM (DRKS00021723), a phase I/II trial assessing safety and efficacy as a composite endpoint when using the bronchial arteries to target primary or secondary lung malignancies. Completion is expected 2023. Table 1 provides a selected overview of currently ongoing trials with comments regarding the crucial characteristics of each study.
In summary, only a small number of clinical trials are currently active, almost all limited to small Phase II concepts. Given the lack of comprehensive data on the clinical benefit of radioembolization, emerging data clearly will not suffice to secure radioembolization as integral part of future treatment strategies and guidelines.
Funding Open Access funding enabled and organized by Projekt DEAL. This study was not supported by any funding.

Declarations
Conflict of interest Jens Ricke declares consulting, advisory arrangements, and research grants and travel grants from Sirtex Medical, and consulting, advisory arrangements and receiving travel grants from BTG. Matthias P. Fabritius has no conflicts of interest to declare.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons. org/licenses/by/4.0/.